Optimistic Outlook on Y-mAbs Therapeutics’ GD2-SADA Platform Despite Developmental Delays

JonesTrading analyst Justin Walsh has reiterated their bullish stance on YMAB stock, giving a Buy rating today.

Justin Walsh’s rating is based on the promising potential of Y-mAbs Therapeutics’ GD2-SADA platform, despite the need for further refinement. The initial results from the Phase I trial demonstrated the feasibility of the platform, although improvements are necessary to enhance tumor uptake and retention. The company plans to implement changes such as using companion imaging agents for better patient selection and replacing the current radiohapten with a proprietary one to improve outcomes.
Although these adjustments will delay significant clinical data readouts until the latter half of 2026 and 2027, Walsh remains optimistic about the platform’s potential to deliver meaningful clinical benefits. The GD2-SADA protein’s tolerability and the absence of significant toxicities are positive indicators. The learnings from the initial trial phase are expected to accelerate future development, and Walsh believes the company’s projected approval timelines for GD2-SADA in various cancers remain achievable.

In another report released today, Oppenheimer also reiterated a Buy rating on the stock with a $15.00 price target.

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of YMAB in relation to earlier this year.